{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:51:03Z","timestamp":1780473063161,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00296-019-04363-z","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T14:42:00Z","timestamp":1562251320000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1851-0856","authenticated-orcid":false,"given":"Ayush","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-0536","authenticated-orcid":false,"given":"Narendra Kumar","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-7450","authenticated-orcid":false,"given":"Saroj Kumar","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-3342","authenticated-orcid":false,"given":"Adarsh","family":"Barwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5136-7254","authenticated-orcid":false,"given":"Ravi Hari","family":"Phulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-8403","authenticated-orcid":false,"given":"Pankaj","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"issue":"11","key":"4363_CR1","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1093\/rheumatology\/kes190","volume":"51","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Higashi S-I, Tomoda K, Tsukano M, Shono M (2012) Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatol Oxf Engl 51(11):2064\u20132069","journal-title":"Rheumatol Oxf Engl"},{"issue":"15","key":"4363_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2146\/ajhp070449","volume":"65","author":"A Sebba","year":"2008","unstructured":"Sebba A (2008) Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm 65(15):1413\u20131418","journal-title":"Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm"},{"issue":"3","key":"4363_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3109\/03009742.2010.530294","volume":"40","author":"K Immonen","year":"2011","unstructured":"Immonen K, Kauppi M, Hakala M (2011) Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis. Scand J Rheumatol 40(3):236\u2013238","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"4363_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s10067-005-0048-6","volume":"25","author":"C Duarte","year":"2006","unstructured":"Duarte C, Gomes C, Correia AJ, Salgado M (2006) Renal amyloidosis: an uncommon complication of juvenile idiopathic arthritis. Clin Rheumatol 25(4):548\u2013549","journal-title":"Clin Rheumatol"},{"issue":"12","key":"4363_CR5","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/rheumatology\/41.12.1428","volume":"41","author":"JC Packham","year":"2002","unstructured":"Packham JC, Hall MA (2002) Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 41(12):1428\u20131435","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4363_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00442095","volume":"135","author":"E Stoeber","year":"1981","unstructured":"Stoeber E (1981) Prognosis in juvenile chronic arthritis. Follow-up of 433 chronic rheumatic children. Eur J Pediatr 135(3):225\u2013228","journal-title":"Eur J Pediatr"},{"issue":"3","key":"4363_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/09273948.2013.791701","volume":"21","author":"A Heiligenhaus","year":"2013","unstructured":"Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21(3):180\u2013191","journal-title":"Ocul Immunol Inflamm"},{"key":"4363_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12703\/P6-21","volume":"6","author":"T Beukelman","year":"2014","unstructured":"Beukelman T (2014) Treatment advances in systemic juvenile idiopathic arthritis. F1000prime Rep 6:21","journal-title":"F1000prime Rep"},{"issue":"42","key":"4363_CR9","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.2174\/0929867325666180522085716","volume":"25","author":"D Poddighe","year":"2018","unstructured":"Poddighe D, Romano M, Gattinara M, Gerloni V (2018) Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem 25(42):5860\u20135893","journal-title":"Curr Med Chem"},{"issue":"9","key":"4363_CR10","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1002\/art.22118","volume":"54","author":"Y Okuda","year":"2006","unstructured":"Okuda Y, Takasugi K (2006) Successful use of a humanised anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54(9):2997\u20133000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4363_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2013.854048","volume":"24","author":"Y Okuda","year":"2014","unstructured":"Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N et al (2014) Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 24(1):137\u2013143","journal-title":"Mod Rheumatol"},{"issue":"9617","key":"4363_CR12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet Lond Engl 371(9617):998\u20131006","journal-title":"Lancet Lond Engl"},{"key":"4363_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04508-2","author":"SH Elmedany","year":"2013","unstructured":"Elmedany SH, Mohamed AE, Galil SMA (2019) Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis. Clin Rheumatol. \nhttps:\/\/doi.org\/10.1007\/s10067-019-04508-2","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4363_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40744-016-0040-4","volume":"3","author":"G Giancane","year":"2016","unstructured":"Giancane G, Consolaro A, Lanni S, Dav\u00ec S, Schiappapietra B, Ravelli A (2016) Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther 3(2):187\u2013207","journal-title":"Rheumatol Ther"},{"issue":"11","key":"4363_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409\u20131417","journal-title":"Rheumatol Int"},{"key":"4363_CR16","doi-asserted-by":"crossref","unstructured":"Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S (2017) Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. BMC Nephrol [Internet] 18. \nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5429510\/\n\n. Accessed 19 May 2018","DOI":"10.1186\/s12882-017-0573-y"},{"issue":"4","key":"4363_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","volume":"44","author":"R Papa","year":"2018","unstructured":"Papa R, Lachmann HJ (2018) Secondary, AA, amyloidosis. Rheum Dis Clin N Am 44(4):585\u2013603","journal-title":"Rheum Dis Clin N Am"},{"issue":"3","key":"4363_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","volume":"24","author":"T Lane","year":"2017","unstructured":"Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S et al (2017) Changing epidemiology of AA amyloidosis: clinical observations over 25\u00a0years at a single national referral centre. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis 24(3):162\u2013166","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"1","key":"4363_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/ncprheum0084","volume":"2","author":"P Woo","year":"2006","unstructured":"Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2(1):28\u201334","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"12","key":"4363_CR20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.autrev.2017.10.007","volume":"16","author":"A De Silvestri","year":"2017","unstructured":"De Silvestri A, Capittini C, Poddighe D, Marseglia GL, Mascaretti L, Bevilacqua E et al (2017) HLA-DRB1 alleles and juvenile idiopathic arthritis: diagnostic clues emerging from a meta-analysis. Autoimmun Rev 16(12):1230\u20131236","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4363_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD (2018) Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol Hoboken NJ 70(1):7\u201317","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"5","key":"4363_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12098-015-1913-1","volume":"83","author":"A Sharma","year":"2016","unstructured":"Sharma A, Gupta A, Mitra S, Nada R, Bhattad S, Singh S (2016) Systemic Juvenile idiopathic arthritis with amyloidosis: an uncommon complication with a favourable outcome. Indian J Pediatr 83(5):477\u2013478","journal-title":"Indian J Pediatr"},{"issue":"2","key":"4363_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00296-009-1331-7","volume":"32","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Lucherini OM, Simonini G, Galeazzi M, Baldari CT, Cimaz R (2012) Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene. Rheumatol Int 32(2):465\u2013467","journal-title":"Rheumatol Int"},{"issue":"3","key":"4363_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5114\/reum.2015.53138","volume":"53","author":"M Kwiatkowska","year":"2015","unstructured":"Kwiatkowska M, Jednacz E, Rutkowska-Sak L (2015) Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome\u2014effective treatment with tocilizumab. Reumatologia 53(3):157\u2013160","journal-title":"Reumatologia"},{"issue":"3","key":"4363_CR25","first-page":"178","volume":"4","author":"M De La Torre","year":"2011","unstructured":"De La Torre M, Arboleya L, Pozo S, Pinto J, Velasco J (2011) Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus 4(3):178\u2013180","journal-title":"NDT Plus"},{"issue":"2","key":"4363_CR26","first-page":"130","volume":"19","author":"N Akhtar","year":"2009","unstructured":"Akhtar N, Kiran S, Hussain A, Suleman BA, Jaleel S (2009) Renal amyloidosis in juvenile rheumatoid arthritis. J Coll Phys Surg Pak JCPSP 19(2):130\u2013132","journal-title":"J Coll Phys Surg Pak JCPSP"},{"issue":"4","key":"4363_CR27","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2013.02.377","volume":"62","author":"A Saha","year":"2013","unstructured":"Saha A, Chopra Y, Theis JD, Vrana JA, Sethi S (2013) AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis Off J Natl Kidney Found 62(4):834\u2013838","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"4","key":"4363_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00467-015-3249-5","volume":"31","author":"R Topaloglu","year":"2016","unstructured":"Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol Berl Ger 31(4):633\u2013640","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"6","key":"4363_CR29","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.4103\/1319-2442.220854","volume":"28","author":"A Saha","year":"2017","unstructured":"Saha A, Pais P, Iyengar AA, Abraham AK (2017) Proteinuria in children with juvenile idiopathic arthritis: making the case for early urinary screening. Saudi J Kidney Dis Transplan 28(6):1408","journal-title":"Saudi J Kidney Dis Transplant"},{"issue":"1","key":"4363_CR30","first-page":"73","volume":"9","author":"J David","year":"1991","unstructured":"David J (1991) Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol 9(1):73\u201378","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"4363_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3904\/kjim.2014.292","volume":"31","author":"SA Han","year":"2016","unstructured":"Han SA, Yoon YM, Lee WS, Kim YS, Shin BC, Chung JH et al (2016) Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumour necrosis factor \u03b1 inhibitor therapy. Korean J Intern Med 31(3):601\u2013604","journal-title":"Korean J Intern Med"},{"issue":"8","key":"4363_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00467-011-1797-x","volume":"26","author":"Y Bilginer","year":"2011","unstructured":"Bilginer Y, Akpolat T, Ozen S (2011) Renal amyloidosis in children. Pediatr Nephrol Berl Ger 26(8):1215\u20131227","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"5","key":"4363_CR33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3349\/ymj.2012.53.5.1045","volume":"53","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Giani T, Fioravanti A, Iacoponi F, Simonini G, Pagnini I et al (2012) Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J 53(5):1045\u20131048","journal-title":"Yonsei Med J"},{"key":"4363_CR34","doi-asserted-by":"crossref","unstructured":"Ugurlu S, Hacioglu A, Adibnia Y, Hamuryudan V, Ozdogan H (2017) Tocilizumab in the treatment of twelve cases with AA amyloidosis secondary to familial Mediterranean fever. Orphanet J Rare Dis [Internet] 12. \nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5450086\/\n\n. Accessed 8 Jun 2019","DOI":"10.1186\/s13023-017-0642-0"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04363-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T23:09:20Z","timestamp":1593731360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04363-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4363"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04363-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"22 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"A written informed consent was taken from the patient\u2019s legal guardian in an appropriate format.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}